Genelux begins dosing in Phase II ovarian cancer trial

US-based oncolytic immunotherapy developer Genelux has started dosing patients in a Phase II clinical trial (VIRO-15) of its clinical-stage candidate GL-ONC1 to treat recurrent ovarian cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news

Related Links:

TapImmune Inc. stock has blossomed in the month since it announced it will merge with a company producing similar cancer-fighting treatments, begin a strategic alliance with Baylor College of Medicine and move to Houston. The stock has more than tripled since the announcement and rose more than 18 percent Friday. TapImmune (Nasdaq: TPIV) develops cancer-fighting immunotherapies that target breast and ovarian cancers. It is merging with Marker Therapeutics Inc., which develops similar therapies,…
Source: Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news
Condition:   Ovarian Cancer Intervention:   Biological: Tableted vaccine (V3-OVA) containing ovarian cancer antigens Sponsor:   Immunitor LLC Recruiting
Source: - Category: Research Source Type: clinical trials
Abstract Anti-ovarian cancer vaccines based on minimal immune determinants uniquely expressed in ovarian cancer biomarkers and absent in the human proteome appear to promise a high level of sensitivity and specificity for early ovarian cancer immunodiagnostics, immunoprevention, and immunotherapy. In this context, the present study analyses three ovarian cancer biomarkers - namely sperm surface protein Sp17, WAP four-disulfide core domain protein 2, and müllerian-inhibiting substance - and describes a methodology for constructing ovarian cancer biomarker-derived oligopeptide constructs that might be useful fo...
Source: Current Drug Discovery Technologies - Category: Drugs & Pharmacology Authors: Tags: Curr Drug Discov Technol Source Type: research
Authors: Farghaly SA Abstract The standard of care for patients with recurrent ovarian cancer is platinum-based combination chemotherapy for those who relapse more than six months after completing adjuvant therapy. The use of biological agents such as bevacizumab has increased progression- free survival (PFS), but has not shown a significant increase in overall survival (OS). Immunotherapy treatment modality is being ac- tively pursued for patients with ovarian cancer. The goal of immunotherapy is to generate a tumor specific, T cell response that decrease residual disease, and protects against future recurrence. C...
Source: European Journal of Gynaecological Oncology - Category: OBGYN Tags: Eur J Gynaecol Oncol Source Type: research
Oncologists in Spain are recruiting patients for the randomized phase of the pleural mesothelioma clinical trial involving ONCOS-102, the promising immunotherapy vaccine. Optimism surrounding the trial stems from encouraging results obtained recently in the six-patient safety cohort used as a precautionary lead-in. The trial involves the vaccine in combination with standard-of-care chemotherapy for patients with inoperable disease. ONCOS-102 is a scientifically engineered adenovirus that is designed to activate a patient’s immune system to selectively target cancer cells. It is being developed by Targovax, a Scandina...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
This article is protected by copyright. All rights reserved. PMID: 29772069 [PubMed - as supplied by publisher]
Source: Immunology - Category: Allergy & Immunology Authors: Tags: Immunology Source Type: research
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
The objective of this study was to investigate tumoral PD-1 and PD-L1 mRNA-expression in a cohort of ovarian cancer (OC) patients in relation to tumor mutations. We analyzed mRNA expression of PD-1, PD-L1 and IFNG by quantitative real-time PCR in tissue of 170 patients with low grade-serous (LGSOC), high-grade serous (HGSOC), endometrioid and clear cell OC compared to 28 non-diseased tissues (ovaries and fallopian tubes) in relation to tumor protein 53 (TP53) and breast cancer gene 1/2 (BRCA1/2) mutation status. TP53-mutated OC strongly expressed PD-L1 compared to TP53 wild-type OC (p = 0.028) and BRCA1/2-mutated OC increa...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Conclusion/Discussions: This pilot study demonstrated the feasibility of our efficient process from identification of neoantigen to production of the neoantigen-targeting cytotoxic TCR-engineered T cells for ovarian cancer and revealed the importance of careful validation of neoantigen-specific-TCR-engineered T cells to avoid severe immune-related adverse events. PMID: 29720506 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
CONCLUSION: The nadir of absolute lymphocyte concentrations is an independent predictor of overall survival and progression free survival. This is an easily measurable biomarker which can be utilized for identifying patients that will be likely to respond to immunomodulation. Furthermore, this evidence showing significant improvement in OS and PFS with two or less cycles with hemoglobin
Source: European Journal of Gynaecological Oncology - Category: OBGYN Tags: Eur J Gynaecol Oncol Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Immunotherapy | Ovarian Cancer | Ovaries | Pharmaceuticals